First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
cetuximab
combination chemotherapy
first-line
observational study
squamous cell carcinoma of head and neck
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
29
01
2023
received:
16
09
2022
accepted:
24
02
2023
medline:
12
5
2023
pubmed:
19
4
2023
entrez:
18
4
2023
Statut:
ppublish
Résumé
ENCORE, an observational, prospective, open-label study, investigated real-world treatment practices and outcomes with cetuximab plus platinum-based therapy (PBT) in first-line (1L) recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). This multinational study aimed to investigate the long-term use of cetuximab plus PBT for 1L R/M SCCHN in a clinical setting. In particular, this study aimed to explore clinical considerations such as the decision to prescribe cetuximab plus PBT in R/M SCCHN, the mode and duration of treatment, and patient outcomes. Previously untreated patients with R/M SCCHN whose planned treatment was cetuximab plus PBT were enrolled from 6 countries. Among 221 evaluable patients, planned treatments included cetuximab plus carboplatin (31.2%), cisplatin plus 5-fluorouracil (31.7%), or carboplatin plus 5-fluorouracil (23.1%); 3.2% included a taxane, and 45.2% did not include 5-fluorouracil. Cetuximab treatment was planned for a fixed duration (≤24 weeks) in 15 patients (6.8%) and until disease progression in 206 (93.2%). Median progression-free survival and overall survival were 6.5 and 10.8 months, respectively. Grade ≥3 adverse events occurred in 39.8% of patients. Serious adverse events occurred in 25.8% of patients; 5.4% were cetuximab-related. In patients with R/M SCCHN, first-line cetuximab plus PBT was feasible and modifiable in a real-world setting with similar toxicity and efficacy as in the pivotal phase III EXTREME trial. EMR 062202-566.
Sections du résumé
BACKGROUND
ENCORE, an observational, prospective, open-label study, investigated real-world treatment practices and outcomes with cetuximab plus platinum-based therapy (PBT) in first-line (1L) recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
AIMS
This multinational study aimed to investigate the long-term use of cetuximab plus PBT for 1L R/M SCCHN in a clinical setting. In particular, this study aimed to explore clinical considerations such as the decision to prescribe cetuximab plus PBT in R/M SCCHN, the mode and duration of treatment, and patient outcomes.
METHODS AND RESULTS
Previously untreated patients with R/M SCCHN whose planned treatment was cetuximab plus PBT were enrolled from 6 countries. Among 221 evaluable patients, planned treatments included cetuximab plus carboplatin (31.2%), cisplatin plus 5-fluorouracil (31.7%), or carboplatin plus 5-fluorouracil (23.1%); 3.2% included a taxane, and 45.2% did not include 5-fluorouracil. Cetuximab treatment was planned for a fixed duration (≤24 weeks) in 15 patients (6.8%) and until disease progression in 206 (93.2%). Median progression-free survival and overall survival were 6.5 and 10.8 months, respectively. Grade ≥3 adverse events occurred in 39.8% of patients. Serious adverse events occurred in 25.8% of patients; 5.4% were cetuximab-related.
CONCLUSION
In patients with R/M SCCHN, first-line cetuximab plus PBT was feasible and modifiable in a real-world setting with similar toxicity and efficacy as in the pivotal phase III EXTREME trial.
CLINICAL TRIAL REGISTRATION NUMBER
EMR 062202-566.
Identifiants
pubmed: 37069784
doi: 10.1002/cnr2.1804
pmc: PMC10172179
doi:
Substances chimiques
Cetuximab
PQX0D8J21J
Platinum
49DFR088MY
Carboplatin
BG3F62OND5
Fluorouracil
U3P01618RT
Cisplatin
Q20Q21Q62J
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1804Informations de copyright
© 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Lancet Oncol. 2021 Jun;22(6):883-892
pubmed: 33989559
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Mayo Clin Proc. 2008 Apr;83(4):489-501
pubmed: 18380996
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Ann Oncol. 2014 Apr;25(4):801-807
pubmed: 24577117
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Front Oncol. 2017 May 09;7:72
pubmed: 28536670
Int J Mol Sci. 2019 Mar 26;20(6):
pubmed: 30917608
Lancet Oncol. 2021 Apr;22(4):463-475
pubmed: 33684370
Front Oncol. 2016 Aug 31;6:199
pubmed: 27630826
Front Oncol. 2019 May 20;9:383
pubmed: 31165040
Lancet Oncol. 2021 Jun;22(6):e228-e229
pubmed: 34087138
Cancer Rep (Hoboken). 2023 May;6(5):e1804
pubmed: 37069784